Research Analysts Set Expectations for RenovoRx Q1 Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Research analysts at Ascendiant Capital Markets upped their Q1 2026 EPS estimates for shares of RenovoRx in a research note issued to investors on Wednesday, April 8th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.08). Ascendiant Capital Markets has a “Buy” rating and a $13.50 price objective on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.40) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s Q3 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.26) EPS and FY2027 earnings at ($0.23) EPS.

RenovoRx (NASDAQ:RNXT) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). RenovoRx had a negative net margin of 994.48% and a negative return on equity of 119.77%. The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.42 million. During the same period in the prior year, the company posted ($0.40) EPS.

Several other brokerages have also recently issued reports on RNXT. JonesTrading upgraded shares of RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. Weiss Ratings restated a “sell (e+)” rating on shares of RenovoRx in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of RenovoRx in a research report on Wednesday, April 8th. Finally, Wall Street Zen cut shares of RenovoRx from a “hold” rating to a “strong sell” rating in a research report on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, RenovoRx has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

RenovoRx Stock Performance

Shares of NASDAQ RNXT opened at $1.03 on Wednesday. RenovoRx has a 52-week low of $0.70 and a 52-week high of $1.45. The firm has a 50 day moving average price of $0.95 and a two-hundred day moving average price of $0.99. The stock has a market cap of $46.40 million, a P/E ratio of -3.22 and a beta of 1.22.

Institutional Investors Weigh In On RenovoRx

Large investors have recently modified their holdings of the company. XTX Topco Ltd increased its position in shares of RenovoRx by 58.6% during the fourth quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock worth $42,000 after buying an additional 18,525 shares during the period. Geode Capital Management LLC increased its position in shares of RenovoRx by 9.9% during the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after buying an additional 31,730 shares during the period. Bleichroeder LP increased its position in shares of RenovoRx by 11.4% during the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after buying an additional 61,379 shares during the period. Wealthspire Advisors LLC acquired a new stake in shares of RenovoRx during the fourth quarter worth $212,000. Finally, Citadel Advisors LLC acquired a new stake in shares of RenovoRx during the third quarter worth $154,000. 3.10% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting RenovoRx

Here are the key news stories impacting RenovoRx this week:

• Positive Sentiment: Ascendiant Capital Markets raised several near?term EPS forecasts (Q1 2026 to ($0.07) from ($0.08); Q3 2026 to ($0.06) from ($0.07); FY2026 to ($0.26) from ($0.28)) and reiterated a Buy rating with a $13.50 price target — a bullish analyst view that likely underpins buying interest. MarketBeat RNXT Coverage
• Positive Sentiment: Clinical data presented at the 2026 SIR Annual Scientific Meeting showed TAMP™ can deliver gemcitabine locally with reduced systemic toxicity in locally advanced pancreatic cancer patients — data that can materially de?risk the program and improve commercial/partnering optionality if confirmed. GlobeNewswire Release
• Neutral Sentiment: Ascendiant also published multi?quarter/annual FY2027 estimates (quarterly EPS centered at about ($0.05)–($0.06); FY2027 at ($0.23)) — useful modeling detail but already reflected in the firm’s bullish $13.50 target. MarketBeat RNXT Coverage
• Negative Sentiment: Underlying fundamentals remain weak: most recent quarter (reported Mar 30) showed an EPS loss in line with estimates but revenue missed consensus, and the company continues to post large negative margins and ROE — reminders of execution and financing risk for investors. MarketBeat RNXT Coverage

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.